- Home
- ADPT vs ICFI Comparison
ADPT vs ICFI Comparison
Compare ADPT & ICFI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADPT
- ICFI
- Stock Information
- Founded
- ADPT 2009
- ICFI 1969
- Country
- ADPT United States
- ICFI United States
- Employees
- ADPT N/A
- ICFI N/A
- Industry
- ADPT Biotechnology: Biological Products (No Diagnostic Substances)
- ICFI Professional Services
- Sector
- ADPT Health Care
- ICFI Consumer Discretionary
- Exchange
- ADPT Nasdaq
- ICFI Nasdaq
- Market Cap
- ADPT 1.4B
- ICFI 1.5B
- IPO Year
- ADPT 2019
- ICFI 2006
- Fundamental
- Price
- ADPT $10.38
- ICFI $82.72
- Analyst Decision
- ADPT Strong Buy
- ICFI Buy
- Analyst Count
- ADPT 7
- ICFI 4
- Target Price
- ADPT $10.57
- ICFI $115.50
- AVG Volume (30 Days)
- ADPT 1.3M
- ICFI 160.4K
- Earning Date
- ADPT 07-31-2025
- ICFI 07-31-2025
- Dividend Yield
- ADPT N/A
- ICFI 0.68%
- EPS Growth
- ADPT N/A
- ICFI 18.33
- EPS
- ADPT N/A
- ICFI 5.82
- Revenue
- ADPT $189,527,000.00
- ICFI $2,012,969,000.00
- Revenue This Year
- ADPT $24.46
- ICFI N/A
- Revenue Next Year
- ADPT $20.25
- ICFI $1.54
- P/E Ratio
- ADPT N/A
- ICFI $14.17
- Revenue Growth
- ADPT 8.61
- ICFI 1.95
- 52 Week Low
- ADPT $2.99
- ICFI $75.91
- 52 Week High
- ADPT $10.87
- ICFI $179.67
- Technical
- Relative Strength Index (RSI)
- ADPT 62.28
- ICFI 42.69
- Support Level
- ADPT $9.90
- ICFI $84.96
- Resistance Level
- ADPT $10.85
- ICFI $89.14
- Average True Range (ATR)
- ADPT 0.48
- ICFI 2.52
- MACD
- ADPT -0.02
- ICFI -0.15
- Stochastic Oscillator
- ADPT 68.39
- ICFI 16.52
About ADPT Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).
About ICFI ICF International Inc.
ICF International Inc provides professional services and technology-based solutions to government and commercial clients, including management, marketing, technology, and policy consulting and implementation services. Its services support clients that operate in four key markets that include Energy, Environment, Infrastructure and Disaster Recovery; Health and Social Programs and Security and Other Civilian & Commercial. The Company's majority clients are United States federal government departments and agencies. It operates in a single segment, which is providing professional services.